Today, COVID-19 is defining our lives. The coronavirus disease outbreak has caught us by surprise resulting in many causalities and

Victor Schut has been appointed as the new Chief Executive Officer (CEO) of AGILeBiotics and co-founder Dr. Andreas A. Bastian

We are proud to announce that AGILeBiotics is the winner of the Investors Forum 2019, which took place at the

We are proud to announce that AGILeBiotics has been awarded the European Soft Matter Infrastructure (EUSMI) grant from from the

We are proud to announce that AGILeBiotics has been awarded the Lead Development Voucher by the Netherlands Antibiotic Development Platform

We are proud to announce that AGILeBiotics has expended its Management Team and Scientific Advisory Board. Victor Schut is the new

We are proud to announce that AGILeBiotics is now a member of the BEAM Alliance, the European AMR innovation hub

Gronigen, The Netherlands. AGILeBiotics BV has raised the next series of investment for the development of novel antibiotics against multidrug-resistant

Supported by the Versneller Innovatieve Ambities (VIA)-subsidy from Samenwerking Noord-Nederland (SNN), AGILeBiotics is developing novel antibiotics for hospital-treated Gram-negative infections. According

AGILeBiotics entered successfully the Health-i-Care program (INTERREG) starting a collaboration with the University Medical Center Groningen (UMCG) and Hospitals in Germany